# Surgery for Relapsed Ovarian Cancer in Precision

> **NCT06602063** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Gynecologic Oncology Group** · enrollment: 33 (estimated)

## Conditions studied

- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma

## Interventions

- **PROCEDURE:** surgery/chemotherapy
- **DRUG:** Iparomlimab/Tuvonralimab

## Key facts

- **NCT ID:** NCT06602063
- **Lead sponsor:** Shanghai Gynecologic Oncology Group
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07
- **Primary completion:** 2030-06
- **Final completion:** 2030-06
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-06-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06602063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06602063, "Surgery for Relapsed Ovarian Cancer in Precision". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06602063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*